Cyclobenzaprine and back pain: a meta-analysis.
BACKGROUND
Back pain is a common problem for which cyclobenzaprine hydrochloride is frequently prescribed.


OBJECTIVE
To perform a systematic review of cyclobenzaprine's effectiveness in the treatment of back pain.


METHODS
We searched MEDLINE, PsycLIT, CINAHL, EMBASE, AIDSLINE, HEALTHSTAR, CANCERLIT, the Cochrane Library, Micromedex, Federal Research in Progress, and the references of reviewed articles, and contacted Merck, Sharpe and Dohme for English-language, randomized, placebo-controlled trials of cyclobenzaprine in adults with back pain. Outcomes included global improvement and 5 specific domains of back pain (local pain, muscle spasm, range of motion, tenderness to palpation, and activities of daily living). Study quality was assessed using the methods of Jadad. Summary outcomes were obtained using a random-effects model.


RESULTS
Patients treated with cyclobenzaprine were nearly 5 times (odds ratio, 4.7; 95% confidence interval, 2.7-8.1) as likely to report symptom improvement by day 14 as were those treated with placebo. Slightly fewer than 3 individuals (2.7; 95% confidence interval, 2.0-4.2) needed treatment for 1 to improve. The magnitude of this improvement was modest, with an effect size of 0.38 to 0.58 in all 5 outcomes (local pain, muscle spasm, tenderness to palpation, range of motion, and activities of daily living). Treatment efficacy for these 5 outcomes was greatest early, in the first few days of treatment, declining after the first week. Patients receiving cyclobenzaprine also experienced more adverse effects, the most common being drowsiness.


CONCLUSIONS
Cyclobenzaprine is more effective than placebo in the management of back pain; the effect is modest and comes at the price of greater adverse effects. The effect is greatest in the first 4 days of treatment, suggesting that shorter courses may be better. Studies comparing the relative value of acetaminophen, nonsteroidal anti-inflammatory drugs, and cyclobenzaprine individually and in combination in the treatment of back pain are needed.
Browning
R
R
Department of Medicine, National Naval Medical Center, Bethesda, MD, USA. browning_robert@hotmail.com
Jackson
J L
JL
O'Malley
P G
PG
D000639:Amitriptyline / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D001416:Back Pain / Q000188:drug therapy*; D006801:Humans; D009125:Muscle Relaxants, Central / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D009125:Muscle Relaxants, Central; D000639:Amitriptyline; C004704:cyclobenzaprine